Researchers from University College London are exploring the potential risks of blood transfusions transmitting harmful brain proteins, such as amyloid-beta, which is linked to Alzheimer's disease and cerebral amyloid angiopathy. This investigation has significant implications for the safety of blood transfusions and may lead to the development of new screening protocols to minimize the risk of transmitting these proteins.
Key Insights
Amyloid-beta proteins have been linked to Alzheimer's disease and cerebral amyloid angiopathy, and historical medical treatments have been shown to transmit these proteins, leading to cases of iatrogenic CAA and Alzheimer's disease. Furthermore, a large Scandinavian epidemiological study found a higher risk of brain bleeds in recipients of blood from donors who later developed multiple brain bleeds, highlighting the need for further research in this area.
